ID   SW626
AC   CVCL_1725
AS   CVCL_IW65
SY   SW-626; SW 626
DR   BTO; BTO:0001881
DR   CLO; CLO_0009197
DR   CLO; CLO_0009222
DR   CLDB; cl4446
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-78
DR   BioGRID_ORCS_Cell_line; 1030
DR   BioSample; SAMN03472756
DR   BioSample; SAMN03472876
DR   cancercelllines; CVCL_1725
DR   CCRID; 4201HUM-CCTCC00112
DR   CCTCC; GDC0112
DR   Cell_Model_Passport; SIDM01168
DR   ChEMBL-Cells; CHEMBL3308130
DR   ChEMBL-Targets; CHEMBL1075593
DR   CLS; 305093
DR   Cosmic; 724882
DR   Cosmic; 844346
DR   Cosmic; 849608
DR   Cosmic; 867865
DR   Cosmic; 897437
DR   Cosmic; 909753
DR   Cosmic; 920358
DR   Cosmic; 948285
DR   Cosmic; 949229
DR   Cosmic; 1044244
DR   Cosmic; 1093559
DR   Cosmic; 1113284
DR   Cosmic; 1312194
DR   Cosmic; 1707572
DR   Cosmic; 2582804
DR   Cosmic; 2674699
DR   Cosmic-CLP; 909753
DR   DepMap; ACH-001399
DR   ECACC; 91091203
DR   EGA; EGAS00001000978
DR   GDSC; 909753
DR   GEO; GSM186459
DR   GEO; GSM186460
DR   GEO; GSM313714
DR   GEO; GSM659406
DR   GEO; GSM784571
DR   GEO; GSM1670509
DR   IARC_TP53; 27252
DR   KCB; KCB 2013039YJ
DR   LINCS_LDP; LCL-1529
DR   PharmacoDB; SW626_1542_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1725
DR   PubChem_Cell_line; CVCL_1725
DR   Wikidata; Q54971190
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=6582512;
RX   PubMed=9698466;
RX   PubMed=10433623;
RX   PubMed=11314036;
RX   PubMed=12068308;
RX   PubMed=20106510;
RX   PubMed=20164919;
RX   PubMed=23415752;
RX   PubMed=25846456;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Problematic cell line: Misclassified. Although established from a surgical specimen from a cystadenocarcinoma of the ovary in a 46 year old female Caucasian, it now seems likely that it was established from an ovarian metastasis of a colonic carcinoma (PubMed=10433623).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Scott and White Clinic; Temple; USA.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg976fs*9 (c.2926_2927insA); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=12068308; PubMed=25846456; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (PubMed=25846456; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262Val (c.785G>T); ClinVar=VCV000428889; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.06%; Native American=0.08%; East Asian, North=0.77%; East Asian, South=0%; South Asian=2.55%; European, North=65.38%; European, South=31.17% (PubMed=30894373).
CC   Misspelling: SWS-26; PubMed=20106510.
CC   Discontinued: CLS; 305093; true.
CC   Derived from site: Metastatic; Ovary; UBERON=UBERON_0000992.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11 (ATCC; PubMed=25877200)
ST   D13S317: 11,12 (Cosmic-CLP)
ST   D16S539: 11
ST   D18S51: 14
ST   D19S433: 14
ST   D21S11: 27,29
ST   D2S1338: 25
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 10,12 (ATCC; Cosmic-CLP)
ST   D7S820: 12 (PubMed=25877200)
ST   D8S1179: 11
ST   FGA: 21,23
ST   Penta D: 9,13
ST   Penta E: 7,11
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=9698466; DOI=10.1006/gyno.1998.5039;
RA   Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene is not a feature of
RT   ovarian cancers.";
RL   Gynecol. Oncol. 70:13-16(1998).
//
RX   PubMed=10433623; DOI=10.1093/jnci/91.15.1327;
RA   Furlong M.T., Hough C.D., Sherman-Baust C.A., Pizer E.S., Morin P.J.;
RT   "Evidence for the colonic origin of ovarian cancer cell line SW626.";
RL   J. Natl. Cancer Inst. 91:1327-1328(1999).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=20106510; DOI=10.1016/j.ygyno.2009.12.002;
RA   Byron S.A., Gartside M.G., Wellens C.L., Goodfellow P.J., Birrer M.J.,
RA   Campbell I.G., Pollock P.M.;
RT   "FGFR2 mutations are rare across histologic subtypes of ovarian
RT   cancer.";
RL   Gynecol. Oncol. 117:125-129(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//